Electromagnetic Information Transfer to Manage Chronic Kidney Disease

Anton Sheikh-Fedorenko
Nov 30, 2019
As explained through physics, molecules, atoms, electrons, and chemical bonds all have unique vibrating energy fields and in actuality, life depends on molecular interactions through those fields. Over the years there have been numerous publications that have confirmed the possibility of transferring, via a carrier substance (such as water), electromagnetic (EM) signatures that contain information and function of active substances. This phenomenon holds great promise due to its non-invasive and safe nature and is gaining significant interest in the clinical realm. In fact, there are a number of clinical studies that have already demonstrated the potential benefits of this approach. Among the studies, the management of chronic kidney disease was looked at.

Chronic kidney disease (CKD) is a condition where the kidney is damaged, or there is a loss in kidney function for three months or more. Anyone, at any age, can get CKD; however, some people are more susceptible than others. For instance, people who have diabetes or high blood pressure have a greater risk of kidney disease. Also, CKD is a serious concern for elderly people. 

This post reviews a publication titled “Biophysical approach to chronic kidney disease management in older patients” by A. Foletti and M. Cozzolino wherein the investigators conducted a pilot study that examined the effect of electromagnetic information transfer through an aqueous system on kidney function of elderly people affected by early-stage CKD.



What did the authors do?


A total of 58 people (28 males and 30 females) with a mean age of 74.8 ± 3.7 years; range 70-80 years and presenting stage 1 or 2 CKD (i.e. estimated glomerular filtration rate > 60 mL/min and normal is 90 mL/min) participated in the study. All the participants had high blood pressure, but did not have diabetes. 

Each participant was treated 10 minutes every 3 months until the end of the study (1-year period) on a full-body mat that emits therapeutic electromagnetic signals. Additionally, each participant periodically was drinking aqueous solutions treated with electromagnetic signals. Estimated glomerular filtration rate (eGFR) values were obtained and recorded before starting the treatment (i.e. baseline) and at the 1-year follow-up.

 

What did the data reveal?


The authors observed that at the end of the investigation, there was a significant increase in the eGFR. The mean eGFR at the 1-year follow-up was 68.9 ± 15.8 compared to the baseline of 64.6 ± 15.6 mL/min (Fig.1.), which corresponds to an improvement of 8.8 % ± 17.7 %. Additionally, when comparing the eGFR values for men and women, it was seen that in men there was an improvement in the GFR of 10.3 % ± 16.6% and in women 9.4 % ± 19%. Moreover, no side effects or adverse reactions were reported during the 1-year investigation period. 

All in all, this preliminary study provides evidence to support the potential use of therapeutic electromagnetic information transfer through an aqueous system to manage early-stage CKD.

Fig. 1. Estimated glomerular filtration rate (eGFR) before and after 1 year of using therapeutic electromagnetic signals directly through the mat and through the water. A higher rate value signifies better kidney function.



What does this mean?


Even though further work is still needed, such as looking at the effect of advanced CKD and using a larger sample size, this study illustrates the promising use of therapeutic electromagnetic information transfer to help people with early-stage CKD. The study was conducted on a human population and showed significant improvement in eGFR over a relatively short period of time (1 year). Overall, these results support the potential use of electromagnetic information transfer therapies, including infoceuticals, as alternative/complementary treatments possessing advantageous characteristics such as being rapid, effective, non-invasive, and producing no side effects. 

On this page, you can find more than 100 available infoceuticals for the urinary system. 

To read the entire publication, please click here.
3
1916